When it comes to health care companies, there's no bigger name than the largest firm in the business: Johnson & Johnson (JNJ -1.86%).
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all. That can make it tough on investors trying to understand this highly diversified company, however: With so many parts, what do you need to keep an eye on? To get a grip on this colossus of the health care sector, let's take a look at Johnson & Johnson's top competitors to its pharmaceutical division and best-selling drugs.
Battling the blockbusters
Let's start by diving into the biggest competition for Johnson & Johnson's biggest drug: Anti-inflammatory therapy Remicade, which made more than $6 billion for the company last year and grew revenues by nearly 12% year-over-year. Remicade's got many uses from treating rheumatoid arthritis to Crohn's disease and more, and its usefulness has made it a standout drug for years.
The immunology market's a big one, however, and Remicade's toughest rivals are bestsellers by their own rights. AbbVie's (ABBV -1.52%) anti-inflammatory medication Humira, used to treat several indications including the aforementioned rheumatoid arthritis, ranks as one of the best-selling drugs in history. Humira pulled in bank-breaking sales of $9.3 billion last year, and with a few more years of patent protection still left, AbbVie's blockbuster will continue to be one of Johnson & Johnson's biggest challengers.
Right up there with Humira is Amgen (AMGN -0.57%) and Pfizer's (PFE -1.83%) Enbrel. The immunology drug and titan in the rheumatology field has years of patent protection left and, like Humira, outsold Remicade last year. Enbrel recorded more than $8 billion in sales last year, although Amgen and Pfizer split the proceeds: The latter controls the drug's sales outside of the U.S. and Canada. Given this drug's patent exclusivity will last the better part of the next decade, however, J&J investors will have to keep a close eye on this Remicade rival.
However, J&J's introduced its own new immunology competitor to fight back against Enbrel and Humira's power. Psoriasis drug Stelara has already reached blockbuster status and saw outstanding sales growth of nearly 39% last year. J&J filed for approval of the drug in treating psoriatic arthritis in the EU and U.S.; if it wins those approvals, Stelara will have a new source of serious revenue that will threaten Enbrel and Humira's positions atop the pharmaceutical world.
Johnson & Johnson's pharmaceuticals branch is more than just immunology, however -- and other drugs bring in more and more rivals to watch.
Remicade might be safe from patent expiration, but some of J&J's other drugs aren't so lucky. Sales of the Levaquin and Floxin family of infectious disease drugs, which had recorded blockbuster sales as recently as 2010, have been hammered by generic competition to the point of less than $100 million in 2012 revenue. Neuroscience drug Concerta has also seen its revenue chipped away by generic competitors; while the drug still managed to exceed $1 billion in revenue last year, it saw a 15% sales decline year-over-year and is poised to dip below that level in 2013.
Prostate cancer pill Zytiga, which has seen excellent growth early in its post-approval life, ran into competition last year after Medivation's (MDVN) rival pill Xtandi received FDA approval. Analysts peg Xtandi's peak sales at between $1 billion and $2 billion, and while Zytiga's almost hit the blockbuster mark already, there should be a good battle between these two in the prostate cancer treatment market in the future.
What about Johnson & Johnson's great new hope -- recently approved diabetes drug Invokana? The treatment picked up FDA approval just days ago, but Invokana enters a highly competitive field looking to take advantage of the rapidly growing diabetes market. Merck's (MRK -0.97%) Januvia and Janumet are the big kids on the diabetes block, and the two drugs combined to pull in 14% of Merck's 2012 pharmaceutical revenue by themselves.
However, Bristol-Myers Squibb's (BMY -1.53%) and AstraZeneca's (AZN -3.53%) diabetes drug Forxiga is a more direct rival to Invokana. The FDA rejected Forxiga last year, but the drug's chances in the U.S . could be improved after the EU granted approval for Forxiga in November. It's too early to say how the battle between Forxiga and Invokana will play out, but with the diabetes market continuing to heat up due to rising rates of obesity, there's no doubt that this will be a prime-time fight.
There are tough competitors across the board for Johnson & Johnson's best-selling pharmaceuticals. From big pharma's biggest players such as Pfizer and Merck to small-time biotech companies like Medivation, J&J will have to keep pressing forward in order to stay ahead of its rivals. Fortunately, this company's size, experience, and power across the entire health care industry make Johnson & Johnson one health care stock you can count on.